Collaboration, Licensing and Other Arrangements - Additional Information (Detail) - USD ($)		1 Months Ended				3 Months Ended		6 Months Ended		12 Months Ended	20 Months Ended
	Jul. 01, 2021	May 31, 2021	Dec. 31, 2020	Sep. 30, 2019	May 31, 2018	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Nov. 30, 2020	Oct. 31, 2018
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue - current			$ 33,275,000			$ 20,126,000		$ 20,126,000		$ 33,275,000
Revenue' collaborations and services						23,280,000	$ 15,114,000	40,716,000	$ 31,349,000
Deferred revenue - long term			1,662,000			1,589,000		1,589,000		1,662,000
Commercial product sales
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue' collaborations and services						9,976,000	6,985,000	18,075,000	$ 14,985,000
Collaboration and License Agreement | United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received												$ 45,000,000.0
Milestone Payment Received											$ 12,500,000
Total transaction price		$ 50,200,000				50,900,000		$ 50,900,000
Increase in total consideration			$ 2,700,000
Revenue, performance obligation satisfied over time, method used, description								The Company determined that the Pre-Commercial Services and Next-gen R&D Services performance obligations will be satisfied over time using the input method based on the costs incurred to date as a percentage of the total estimated costs to fulfill the contract.
Revenue, performance obligation satisfied over time, method used, explanation								Incurred cost represents work performed, which corresponds with, and thereby best depicts, the transfer of control to the customer. The Facility Expansion Services performance obligation would be recognized as control of manufactured products is transferred to the customer.
Deferred revenue - current						20,000,000.0		$ 20,000,000.0
Collaboration and License Agreement | United Therapeutics Corporation | Equipment | Deposit from Customer
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Proceeds from related party		5,300,000
Collaboration and License Agreement | United Therapeutics Corporation | Additional Clinical Supplies
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price						700,000		$ 700,000
Collaboration and License Agreement | United Therapeutics Corporation | R&D Services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price		18,300,000
Revenue, performance obligation, expected timing of satisfaction, description								The R&D Services performance obligation was allocated a total of $18.3 million, which will be recognized on a ratable basis from May 2021 through October 2021; the estimated date when the performance obligation for the initial development services will be substantially completed.
Collaboration and License Agreement | United Therapeutics Corporation | Pre-Commercial Services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price		4,600,000
Collaboration and License Agreement | United Therapeutics Corporation | Next-gen R&D Services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price		7,200,000
Collaboration and License Agreement | United Therapeutics Corporation | Facility Expansion Services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price		$ 20,700,000
Collaboration and License Agreement | United Therapeutics Corporation | Clinical Supplies
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price						105,800,000		$ 105,800,000
Collaboration and License Agreement | United Therapeutics Corporation | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional option exercise and development milestone payments to be receive						40,000,000.0		40,000,000.0
Co-Promotion Agreement | Vertice Pharma LLC
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price						6,300,000		6,300,000
Co-Promotion Agreement | Other Assets | Vertice Pharma LLC
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contract asset						100,000		100,000
Amendment to Co Promotion Agreement | Vertice Pharma LLC | Subsequent Event
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Percentage of modification of previously fixed consideration	50.00%
Supply and Distribution Agreement | Commercial product sales | Biomm
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue' collaborations and services				$ 700,000			$ 200,000	0		$ 0
License and Distribution Agreement | Cipla Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue - current						100,000		100,000
Marketing and distribution agreement date					2018-05
Deferred revenue						1,700,000		1,700,000
Deferred revenue - long term						$ 1,600,000		$ 1,600,000